Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential
Skin is the most immunogenic component of a vascularized composite allograft (VCA) and is the primary trigger and target of rejection. The skin is directly accessible for visual monitoring of acute rejection (AR) and for directed biopsy, timely therapeutic intervention, and manage...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/495212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545749056880640 |
|---|---|
| author | Jonas T. Schnider Matthias Weinstock Jan A. Plock Mario G. Solari Raman Venkataramanan Xin Xiao Zheng Vijay S. Gorantla |
| author_facet | Jonas T. Schnider Matthias Weinstock Jan A. Plock Mario G. Solari Raman Venkataramanan Xin Xiao Zheng Vijay S. Gorantla |
| author_sort | Jonas T. Schnider |
| collection | DOAJ |
| description | Skin is the most immunogenic component of a vascularized composite allograft (VCA) and is the primary trigger and target of rejection.
The skin is directly accessible for visual monitoring of acute rejection (AR) and for directed biopsy, timely therapeutic intervention, and management of AR.
Logically, antirejection drugs, biologics, or other agents delivered locally to the VCA may reduce the need for systemic immunosuppression with its adverse effects.
Topical FK 506 (tacrolimus) and steroids have been used in clinical VCA as an adjunct to systemic therapy with unclear beneficial effects. However, there are no commercially available topical formulations for other widely used systemic immunosuppressive drugs such as mycophenolic acid, sirolimus, and everolimus. Investigating the site-specific therapeutic effects and efficacy of systemically active agents may enable optimizing the dosing, frequency, and duration of overall immunosuppression in VCA with minimization or elimination of long-term drug-related toxicity. |
| format | Article |
| id | doaj-art-e7d221f0cc844cc4a8d3b2def51ee463 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-e7d221f0cc844cc4a8d3b2def51ee4632025-02-03T07:24:49ZengWileyClinical and Developmental Immunology1740-25221740-25302013-01-01201310.1155/2013/495212495212Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and PotentialJonas T. Schnider0Matthias Weinstock1Jan A. Plock2Mario G. Solari3Raman Venkataramanan4Xin Xiao Zheng5Vijay S. Gorantla6Department of Plastic and Reconstructive Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USADepartment of Plastic and Reconstructive Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USADepartment of Plastic and Reconstructive Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USADepartment of Plastic and Reconstructive Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USADepartment of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15261, USADepartment of Plastic and Reconstructive Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USADepartment of Plastic and Reconstructive Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USASkin is the most immunogenic component of a vascularized composite allograft (VCA) and is the primary trigger and target of rejection. The skin is directly accessible for visual monitoring of acute rejection (AR) and for directed biopsy, timely therapeutic intervention, and management of AR. Logically, antirejection drugs, biologics, or other agents delivered locally to the VCA may reduce the need for systemic immunosuppression with its adverse effects. Topical FK 506 (tacrolimus) and steroids have been used in clinical VCA as an adjunct to systemic therapy with unclear beneficial effects. However, there are no commercially available topical formulations for other widely used systemic immunosuppressive drugs such as mycophenolic acid, sirolimus, and everolimus. Investigating the site-specific therapeutic effects and efficacy of systemically active agents may enable optimizing the dosing, frequency, and duration of overall immunosuppression in VCA with minimization or elimination of long-term drug-related toxicity.http://dx.doi.org/10.1155/2013/495212 |
| spellingShingle | Jonas T. Schnider Matthias Weinstock Jan A. Plock Mario G. Solari Raman Venkataramanan Xin Xiao Zheng Vijay S. Gorantla Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential Clinical and Developmental Immunology |
| title | Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential |
| title_full | Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential |
| title_fullStr | Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential |
| title_full_unstemmed | Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential |
| title_short | Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential |
| title_sort | site specific immunosuppression in vascularized composite allotransplantation prospects and potential |
| url | http://dx.doi.org/10.1155/2013/495212 |
| work_keys_str_mv | AT jonastschnider sitespecificimmunosuppressioninvascularizedcompositeallotransplantationprospectsandpotential AT matthiasweinstock sitespecificimmunosuppressioninvascularizedcompositeallotransplantationprospectsandpotential AT janaplock sitespecificimmunosuppressioninvascularizedcompositeallotransplantationprospectsandpotential AT mariogsolari sitespecificimmunosuppressioninvascularizedcompositeallotransplantationprospectsandpotential AT ramanvenkataramanan sitespecificimmunosuppressioninvascularizedcompositeallotransplantationprospectsandpotential AT xinxiaozheng sitespecificimmunosuppressioninvascularizedcompositeallotransplantationprospectsandpotential AT vijaysgorantla sitespecificimmunosuppressioninvascularizedcompositeallotransplantationprospectsandpotential |